LXRX vs CORT

For growth investors, Lexicon Pharmaceuticals, Inc.

(LXRX) is the stronger pick with 60. 2% revenue growth year-over-year, versus 12. 8% for Corcept Therapeutics Incorporated (CORT). Corcept Therapeutics Incorporated (CORT) offers the better valuation at 63. 6x trailing P/E (138. 9x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +140.

2%, compared to -64. 1% for Lexicon Pharmaceuticals, Inc. (LXRX). Over 10 years, the gap is even starker: CORT returned +991. 0% versus LXRX's -86. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lexicon Pharmaceuticals, Inc.

(LXRX) is the lower-risk stock at 1. 46β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 22% more volatile than LXRX relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 58% for Lexicon Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lexicon Pharmaceuticals, Inc.

(LXRX) is pulling ahead at 60. 2% versus 12. 8% for Corcept Therapeutics Incorporated (CORT). On earnings-per-share growth, the picture is similar: Lexicon Pharmaceuticals, Inc. grew EPS 77. 8% year-over-year, compared to -33. 3% for Corcept Therapeutics Incorporated. Over a 3-year CAGR, LXRX leads at 610. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.

1% net margin versus -101. 1% for Lexicon Pharmaceuticals, Inc. — meaning it keeps 13. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CORT leads at 5. 9% versus -98. 2% for LXRX. At the gross margin level — before operating expenses — LXRX leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LXRX: 275.

0% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Corcept Therapeutics Incorporated (CORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+991.

0% 10Y return). Both have compounded well over 10 years (CORT: +991. 0%, LXRX: -86. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LXRX is a small-cap high-growth stock; CORT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.